Xortx Therapeutics Inc (XRTX)

May 22, 2025

XORTX Therapeutics looks to raise $3M through private placement - MSN

May 22, 2025

May 20, 2025

XRTX Initiates $3 Million Private Placement to Fund Key Projects - GuruFocus

May 20, 2025

May 19, 2025

XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program - Nasdaq

May 19, 2025

May 19, 2025

MT Newswires Canada Stocks To Watch: Endeavour Mining; Quantum BioPharma; XORTX Therapeutics - marketscreener.com

May 19, 2025

May 19, 2025

XORTX Announces USD $3 Million Offering - GlobeNewswire

May 19, 2025

May 19, 2025

XORTX Therapeutics Announces $3 Million Offering to Advance Gout Programs - TipRanks

May 19, 2025

May 19, 2025

Late-Stage Biotech XORTX Secures $3M Funding to Advance Novel Gout Treatment Program - Stock Titan

May 19, 2025

May 18, 2025

XORTX Therapeutics Inc. announced that it expects to receive $2.999999 million in funding - marketscreener.com

May 18, 2025

May 16, 2025

XORTX Therapeutics reports Q1 financials to SEC By Investing.com - Investing.com South Africa

May 16, 2025

May 16, 2025

XORTX Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 16, 2025

May 16, 2025

XORTX Therapeutics reports Q1 financials to SEC - Investing.com

May 16, 2025

May 01, 2025

XORTX Therapeutics Delays Yearly Report Filing - TipRanks

May 01, 2025

Apr 30, 2025

XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com

Apr 30, 2025

Apr 30, 2025

XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks

Apr 30, 2025

Apr 30, 2025

XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025

Apr 30, 2025

XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025

Apr 30, 2025

XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire

Apr 30, 2025

Apr 30, 2025

XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025

Apr 28, 2025

XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com

Apr 28, 2025

Apr 28, 2025

XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks

Apr 28, 2025

Apr 28, 2025

XORTX Announces Grant of European Patent - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan

Apr 28, 2025

Apr 18, 2025

XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN

Apr 18, 2025

Apr 18, 2025

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus

Apr 18, 2025

Apr 18, 2025

XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN

Apr 18, 2025

Apr 17, 2025

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire

Apr 17, 2025

Apr 17, 2025

XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan

Apr 17, 2025

Apr 11, 2025

XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail

Apr 11, 2025

Apr 09, 2025

1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail

Apr 09, 2025

Apr 01, 2025

XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks

Apr 01, 2025

Mar 26, 2025

XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks

Mar 26, 2025

Mar 19, 2025

XORTX Announces Update for Discussion with the FDA - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com

Mar 19, 2025

Mar 19, 2025

XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks

Mar 19, 2025

Mar 19, 2025

XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com

Mar 19, 2025

Mar 19, 2025

XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com

Mar 19, 2025

Mar 19, 2025

XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan

Mar 19, 2025

Feb 24, 2025

Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News

Feb 24, 2025

Feb 24, 2025

XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com

Feb 24, 2025

Feb 24, 2025

XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks

Feb 24, 2025

Feb 24, 2025

XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire

Feb 24, 2025

Feb 24, 2025

Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan

Feb 24, 2025

Feb 15, 2025

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com

Feb 15, 2025

Jan 29, 2025

XORTX to Present at Microcap Conference - GlobeNewswire

Jan 29, 2025

Jan 29, 2025

XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks

Jan 29, 2025

Jan 29, 2025

Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan

Jan 29, 2025

Jan 24, 2025

XORTX Therapeutics Announces Auditor Transition - MSN

Jan 24, 2025

Jan 22, 2025

XORTX Announces Change of Auditor - TipRanks

Jan 22, 2025

Jan 21, 2025

XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks

Jan 21, 2025